| Login
Wednesday, March 10, 2010
   Search

Click here for the biographies of invited speakers.

Wednesday 25 March

8:30AM - 9:30AM Session 1 - IBMS / ANZBMS - CABS joint Symposium
Chair: Toshi Yoneda, Rob Coleman
9:30AM - 10:30AM Session 2 - IBMS / ANZBMS - CABS joint Orals
Chair: Graeme Jones, Jackie Center
10:30AM - 11:00AM Refreshment Break
11:00AM - 12:00AM Session 3 - IBMS / ANZBMS - CABS joint Orals II
Chair: Theresa Guise, Julian Quinn
  Nicole Abdul: Inhibiting Glycogen Synthase Kinase-3 (GSK-3) Prevents the Development of Myeloma Bone Disease    abs#008
  Andreas Evdokiou: Apomab, a fully human agonistic DR5 monoclonal antibody inhibits tumour growth and osteolysis in murine models of breast cancer development and progression.    abs#009
  Andrew Douglas Chantry: Blockade of the ALK1 receptor reduces tumour microvessel density and prevents the development of osteolytic bone disease in the 5T2MM murine model of myeloma    abs#011
12:00PM - 1:00PM CABS Lunch
1:00PM - 3:00PM Session 4 - Multiple Myeloma and Myeloproliferative Disease
Chair: Peter Croucher, Toshio Matsumoto
  Masahiro Abe: Mutual interaction between myeloma cells and bone marrow microenvironment    abs#013
  Louise Purton: The bone microenvironment and myeloproliferative disease    abs#014
  Terry Golombick: The potential role of curcumin (diferuloylmethane) in patients with MGUS[Monoclonal Gammopathy of Undetermined Significance].    abs#015
  Michelle Lawson: Localising Individual Myeloma Cells to the Myeloma 'Niche' in Bone using Multiphoton Microscopy.    abs#016
  David Smith: Monitoring myeloma development in bone using computational modeling    abs#017
  Clive Buckle: Soluble Rank Ligand Produced by Myeloma Cells Contributes to Generalised Bone Loss in Multiple Myeloma.    abs#018
  Cory Xian: Mechanisms and prevention of cancer chemotherapy-induced bone growth defects    abs#019
3:00PM - 4:00PM Refreshments and Posters
  Eitan Amir: Trials and Trepidations - Setting Up A Canadian Bone Metastasis Research Program    abs#051
  Eitan Amir: Discordance Between Hormone Receptor Profile of Primary Breast Cancer and Metastatic Bone Disease: Should Bone Marrow Biopsy be Considered a Standard of Care?    abs#052
  Vanessa Cheung: Identification of PTHrP regulated genes in breast cancer cells    abs#053
  Peter Diamond: APO2L/trail inhibits tumour growth and bone destruction in a murine model of multiple myeloma    abs#054
  anna georgieva: Modeling Wnt siganling pathway and its regulation of bone mass    abs#055
  Hisatsugu Goto: Combined therapy with anti-parathyroid hormone-related protein antibody and zoledronic acid for multiple organ metastases of small cell lung cancer cells in severe combined immunodeficient mice .    abs#056
  Agatha Labrinidis: Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in both an immunodeficient and immunocompetent animal model.    abs#057
  Sally Martin: CXCL12 Expression is Regulated by HIF-2 a in Multiple Myeloma Plasma Cells    abs#058
  Sang Ho Moon: Parachordoma of Inguinal Region     abs#059
  Kimberly Morgan: Benign bone tumor excision and graft incorporation in 51 patients: average 22 months follow up.    abs#060
  Carl A Power: Combined Docetaxel and Zoledronic Acid Treatment for Bone Metastatic Murine Prostate Cancer.    abs#061
  Erik Thompson: Targeting Matrix Metalloproteinase-13 (MMP13) in Human Breast Cancer Model Systems    abs#062
  Kate Vandyke: The tyrosine kinase inhibitor dasatinib dysregulates bone remodelling in vivo    abs#063
  Mark Waltham: The antioxidant N-acetylcysteine and its therapeutic potential in breast-to-bone metastasis    abs#064
  Alana Welm: The role of Macrophage Stimulating Protein in metastasis of breast cancer to bone    abs#065
  Masahiro Abe: Bone marrow stromal cells suppress anti-myeloma effects of gammadeltaT cells    abs#066
4:00PM - 6:00PM Session 5 - The Antitumor Potential of Bisphosphonates Realized?
Session sponsored by: Novartis Oncology
  Richard Bell: Osteonecrosis of the Jaw (ONJ): impact on management of skeletal complications of cancer.    abs#020
  Philippe Clezardin: Insights into the Antitumor effects of Bisphosphonates from preclinical models    abs#042
  Richard de Boer: Evidence of the Antitumour activity of Bisphosphonates in the adjuvant and metastatic settings    abs#041
7:00PM - 11:30PM Conference Dinner & Awards

Thursday 26 March

8:30AM - 10:00AM Session 6 - Bisphosphonates in Therapy
Chair: Markus Seibel, Sandy Paterson
  Mark Schifter: Osteonecrosis of the Jaws: incidence, staging, management and prevention – a dental viewpoint.    abs#021
  Eitan Amir: Skeletal related events (SREs) in patients with bone metastases from breast cancer treated with intravenous (i.v.) bisphosphonates (BPs) in the non-trial setting    abs#022
  Gabri van der Pluijm: Bisphosphonate-Targeted Liposomes for Detection and Treatment of Bone Metastases    abs#023
10:00AM - 10:30AM Refreshment Break
10:30AM - 12:30PM Session 7 - EMT and Cancer Spread
Chair: Erik Thompson
  Jean Thiery: Epithelial-Mesenchymal Transition And Its Significance For Bone Marrow Micrometastasis Formation    abs#024
  Jianhua Luo: Integrin α7, Mutated In Prostate Cancer, Liver Cancer, Glioblastoma Multiforme and Leiomyosarcoma, May Be A Tumor Suppressor Gene    abs#025
  Saburo Sone: Validation of Molecular-targeted Therapy in Bone Metastasis Models of Lung Cancer    abs#026
12:30PM - 1:30PM CABS Lunch
1:30PM - 3:30PM Session 8 - Drug Therapies
Chair: Colin Dunstan, Clive Buckle
  Markus Seibel: Markers of Bone Turnover Metastatic Bone Disease    abs#027
  Peter Ebeling: Skeletal Effects of Anti-Cancer Therapies and their Treatment.    abs#028
  Li Laine Ooi: 1,25-dihydroxy-vitamin D3 protects against breast cancer-induced bone resorption.    abs#029
  Eitan Amir: A Phase II Trial Exploring The Effects Of High Dose (10,000 IU/day) Vitamin D In Breast Cancer Patients With Bone Metastases    abs#030
  Steve Bouralexis: Parathyroid Hormone- related Protein (PTHrP) and TRAIL-Mediated Apoptosis in Bresat Cancer.    abs#031
  Swati Biswas: Osteoblasts Take More Active Role in Bone Metastasis by Mediating Motility and Invasion    abs#032
  Elizabeth Williams: Targeting the bone environment through multiple pathways reduces bone metastasis in a xenograft model of disseminated bladder cancer    abs#033
3:30PM - 4:30PM Refreshment Break
4:00PM - 6:00PM Session 8 - New Molecular Targets
Chair: Jianhua Luo, Pamela Russell
  Yibin Kang: Bone metastasis signatures: novel insights from functional genomics    abs#035
  Eitan Amir: An Exploratory Study of the Differential Expression of Candidate Genes in Bone Metastasis Biopsies and Bone Marrow Aspirates From the Same Patient.    abs#036
  Yu Zheng: RANKL induces tumour-derived IL-6 expression in breast cancer metastasis to bone    abs#037
  Ally Chau: Intracellular Osteoprotegerin Increases Breast Tumour Growth and Osteolysis    abs#038
  Judith Clements: Kallikrein-related peptidases promote invasion and bone metastasis in prostate cancer    abs#039
  Ming Zhang: Increased COX2 expression enhances tumor-induced osteoclastic lesions in breast cancer bone metastasis    abs#040
6:00PM - 6:30PM Conference Summary / Close

Home :: About CABS :: Meetings :: Resources :: Contact Us

Privacy Statement | Terms Of Use | Copyright 2005 Cancer and Bone Society